Ratings by UBS (Navin Jacob)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/5/2024 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/17/2024 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 9/27/2023 | Intercept Pharmaceuticals | ICPT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/14/2023 | Intercept Pharmaceuticals | ICPT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/1/2023 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 4/25/2023 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/10/2023 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2023 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2023 | Intercept Pharmaceuticals | ICPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 9/22/2022 | Eli Lilly | LLY | Upgrade | Buy (Neutral) |
296.48 (732.20) |
146.96% | Details | |
| 8/1/2022 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2022 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/28/2022 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2022 | Abbvie | ABBV | Downgrade | Neutral (Buy) |
145.27 (167.80) |
15.51% | Details | |
| 11/29/2021 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 11/29/2021 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 9/14/2021 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/25/2021 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/6/2021 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2021 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2021 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/19/2021 | Royalty Pharma | RPRX | Maintain | Buy (Buy) |
|
Details | ||
| 3/9/2021 | DHT Holdings Inc | DHT | New Coverage | Buy (N/A) |
5.71 (11.28) |
97.55% | Details | |
| 2/2/2021 | Applied Therapeutics | APLT | Maintain | Buy (N/A) |
|
Details | ||
| 12/22/2020 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/11/2020 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2020 | Royalty Pharma | RPRX | Upgrade | Buy (Neutral) |
40.13 (27.98) |
-30.28% | Details | |
| 7/13/2020 | Royalty Pharma | RPRX | New Coverage | Neutral (N/A) |
48.36 (27.98) |
-42.14% | Details | |
| 6/30/2020 | Intercept Pharmaceuticals | ICPT | Downgrade | Neutral (Buy) |
77.49 (19.00) |
-75.48% | Details | |
| 6/17/2020 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 6/17/2020 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2020 | Applied Therapeutics | APLT | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2020 | Gilead Sciences | GILD | Downgrade | Neutral (Buy) |
77.78 (67.08) |
-13.76% | Details | |
| 4/21/2020 | Eli Lilly | LLY | Downgrade | Neutral (Buy) |
157.29 (732.20) |
365.51% | Details | |
| 4/13/2020 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2020 | Rapt Therapeutics | RAPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2020 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2020 | Applied Therapeutics | APLT | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2020 | Applied Therapeutics | APLT | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2020 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2019 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/12/2019 | Allergen | AGN | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2019 | Abbvie | ABBV | Upgrade | Buy (Neutral) |
69.49 (167.80) |
141.47% | Details | |
| 8/15/2019 | Elanco Animal Health | ELAN | Upgrade | Neutral (Sell) |
28.51 (13.31) |
-53.31% | Details | |
| 5/28/2019 | Mylan | MYL | Maintain | Neutral (N/A) |
|
Details | ||
| 5/28/2019 | Teva Pharma | TEVA | Downgrade | Neutral (Buy) |
10.87 (13.01) |
19.69% | Details | |
| 2/25/2019 | Pfizer | PFE | New Coverage | Neutral (N/A) |
42.14 (26.27) |
-37.66% | Details | |
| 2/25/2019 | Merck | MRK | New Coverage | Buy (N/A) |
79.83 (127.00) |
59.09% | Details | |
| 2/14/2019 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2019 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2019 | Intercept Pharmaceuticals | ICPT | New Coverage | Buy (N/A) |
113.45 (19.00) |
-83.25% | Details | |
| 1/23/2019 | Teva Pharma | TEVA | Upgrade | Buy (Neutral) |
18.82 (15.97) |
-15.14% | Details |
